ATE546529T1 - Optimierte expression von hpv 31 l1 in hefe - Google Patents

Optimierte expression von hpv 31 l1 in hefe

Info

Publication number
ATE546529T1
ATE546529T1 AT04757990T AT04757990T ATE546529T1 AT E546529 T1 ATE546529 T1 AT E546529T1 AT 04757990 T AT04757990 T AT 04757990T AT 04757990 T AT04757990 T AT 04757990T AT E546529 T1 ATE546529 T1 AT E546529T1
Authority
AT
Austria
Prior art keywords
hpv31
yeast
polynucleotides
synthetic
protein
Prior art date
Application number
AT04757990T
Other languages
English (en)
Inventor
Kathrin Jansen
Loren Schultz
Michael Neeper
Henry Markus
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE546529T1 publication Critical patent/ATE546529T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04757990T 2003-03-24 2004-03-19 Optimierte expression von hpv 31 l1 in hefe ATE546529T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45717203P 2003-03-24 2003-03-24
PCT/US2004/008677 WO2004084831A2 (en) 2003-03-24 2004-03-19 Optimized expression of hpv 31 l1 in yeast

Publications (1)

Publication Number Publication Date
ATE546529T1 true ATE546529T1 (de) 2012-03-15

Family

ID=33098208

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04757990T ATE546529T1 (de) 2003-03-24 2004-03-19 Optimierte expression von hpv 31 l1 in hefe

Country Status (22)

Country Link
US (2) US7276243B2 (de)
EP (1) EP1608767B1 (de)
JP (1) JP4505452B2 (de)
KR (1) KR101080628B1 (de)
CN (1) CN100506999C (de)
AT (1) ATE546529T1 (de)
AU (1) AU2004224335B2 (de)
BR (1) BRPI0408639B8 (de)
CA (1) CA2519112C (de)
EC (1) ECSP056032A (de)
ES (1) ES2381964T3 (de)
FR (1) FR15C0079I2 (de)
HK (1) HK1090953A1 (de)
IL (1) IL171067A (de)
IS (1) IS2859B (de)
MX (1) MXPA05010285A (de)
NL (1) NL300772I1 (de)
NO (2) NO341527B1 (de)
NZ (1) NZ542246A (de)
RU (1) RU2356943C2 (de)
WO (1) WO2004084831A2 (de)
ZA (1) ZA200507178B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CA2560487C (en) * 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
WO2005123762A2 (en) * 2004-06-18 2005-12-29 Indian Immunologicals Ltd Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16
JP2006262846A (ja) * 2005-03-25 2006-10-05 Niigata Bio Research Park Kk 酵母による２−デオキシ−シロ−イノソースの合成および精製する方法並びに得られた２−デオキシ−シロ−イノソース
US20100203496A1 (en) * 2005-04-28 2010-08-12 Taddeo Frank J Fluorescent Multiplex HPV PCR Assays
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
EP2129394B1 (de) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Impfstoffzusammensetzung gegen papillomavirus
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
CN101835797A (zh) 2007-11-23 2010-09-15 上海泽润生物科技有限公司 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
US20110201086A1 (en) 2010-02-12 2011-08-18 Otsuka Pharmaceutical Co., Ltd. Method for producing recombinant virus
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
JP6050811B2 (ja) 2011-06-24 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルミニウムアジュバントを含むｈｐｖワクチン製剤およびその産生方法
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN107916234A (zh) * 2012-03-28 2018-04-17 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv6 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因，及载体，菌株，表达方法
EP3057612B1 (de) 2013-10-16 2020-05-06 Merck Sharp & Dohme Corp. Verfahren zur herstellung von wärmestabilen getrockneten impfstoffformulierungen
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
WO2016057954A2 (en) * 2014-10-10 2016-04-14 Board Of Regents Of The University Of Texas System Exogenous terminators for controlling fungal gene expression
WO2016104923A1 (ko) * 2014-12-26 2016-06-30 아이진 주식회사 인유두종 바이러스의 바이러스 유사 입자 제조방법
CN106148359A (zh) * 2015-03-30 2016-11-23 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
EP3385273A4 (de) * 2015-12-04 2019-08-07 Xiamen University Mutant des menschlichen papillomavirus-typ-58-l1-proteins
WO2021013062A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒31型l1蛋白
JP2023516904A (ja) 2020-02-14 2023-04-21 メルク・シャープ・アンド・ドーム・エルエルシー Ｈｐｖワクチン
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
TW202313658A (zh) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv疫苗
WO2023023152A1 (en) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
CA2296067C (en) 1997-07-09 2008-10-07 The University Of Queensland Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
FR2768748B1 (fr) * 1997-09-24 2001-06-08 Rhone Poulenc Agrochimie Recodage de sequences d'adn permettant leur expression dans les levures et levures transformees obtenues
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
AU753391B2 (en) * 1998-08-14 2002-10-17 Merck Sharp & Dohme Corp. Protein delivery system using human papillomavirus virus-like particles
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
IL154009A0 (en) 2000-07-21 2003-07-31 Glaxo Group Ltd Codon-optimized papilloma virus sequences
AU2001267896A1 (en) 2000-07-26 2002-02-05 Shinko Pantec Co., Ltd. Hydrogen/oxygen supply system
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens

Also Published As

Publication number Publication date
NO341527B1 (no) 2017-12-04
US20060177817A1 (en) 2006-08-10
WO2004084831A2 (en) 2004-10-07
US7276243B2 (en) 2007-10-02
FR15C0079I1 (de) 2016-08-01
MXPA05010285A (es) 2005-11-17
ES2381964T3 (es) 2012-06-04
US20080166371A1 (en) 2008-07-10
NL300772I2 (de) 2015-12-29
AU2004224335A1 (en) 2004-10-07
JP2006523099A (ja) 2006-10-12
BRPI0408639B1 (pt) 2020-08-18
ZA200507178B (en) 2006-08-30
ECSP056032A (es) 2006-01-27
AU2004224335B2 (en) 2010-01-28
RU2005132603A (ru) 2006-04-27
RU2356943C2 (ru) 2009-05-27
WO2004084831A3 (en) 2004-11-11
JP4505452B2 (ja) 2010-07-21
BRPI0408639B8 (pt) 2021-05-25
NZ542246A (en) 2007-12-21
HK1090953A1 (en) 2007-01-05
NL300772I1 (de) 2015-12-29
BRPI0408639A (pt) 2006-03-28
CN1761759A (zh) 2006-04-19
CA2519112A1 (en) 2004-10-07
CA2519112C (en) 2012-09-11
NO20054889D0 (no) 2005-10-21
IL171067A (en) 2011-11-30
KR20050119141A (ko) 2005-12-20
EP1608767B1 (de) 2012-02-22
EP1608767A2 (de) 2005-12-28
CN100506999C (zh) 2009-07-01
NO2018010I1 (no) 2018-03-27
KR101080628B1 (ko) 2011-11-08
IS8019A (is) 2005-09-12
FR15C0079I2 (fr) 2016-11-25
NO20054889L (no) 2005-12-19
US7482428B2 (en) 2009-01-27
EP1608767A4 (de) 2006-08-30
IS2859B (is) 2013-12-15

Similar Documents

Publication Publication Date Title
NO2018010I1 (no) HPV 31 L1 protein
TW200602490A (en) Optimized expression of HPV 52 L1 in yeast
EP1687329B8 (de) Optimierte expression von hpv-58-l1 in hefe
MY140664A (en) Optimized expression of hpv 45 l1 in yeast
WO2003077942A3 (en) Virus-like particles of human papillomavirus
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
KR987000420A (ko) 정제된 파필로마바이러스 단백질(Purified papillomavirus proteins)
DE602005022458D1 (de) Impfstoff gegen humanes papillomavirus zur oralen verabreichung
TW200607858A (en) Optimized expression of HPV 31 L1 in yeast
DE69924262D1 (de) Verfahren zur herstellung von durch hefe exprimierte hpv typs 6 und 16 kapsid-proteinen
EP1427443A4 (de) Vakzine mit papilloma-virus-e-proteinen, die durch einen viralen vektor abgegeben werden
MY138895A (en) Optimized expression of hpv 31 l1 in yeast
TH108752B (th) การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์
TH82139B (th) การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์
AR045249A1 (es) Expresion optimizada de hpv 31 l1 en levadura